Suppr超能文献

Survivin 反应型、条件复制型腺病毒在成人 T 细胞白血病/淋巴瘤中诱导强烈的细胞毒性作用。

A survivin-responsive, conditionally replicating adenovirus induces potent cytocidal effects in adult T-cell leukemia/lymphoma.

机构信息

Department of Clinical Oncology, Course of Advanced Therapeutics, Kagoshima University Graduate School of Medical and Dental Sciences, 8-35-1 Sakuragaoka, Kagoshima, 890-8520, Japan.

Department of Hematology and Rheumatology, Kagoshima University Hospital, Kagoshima, Japan.

出版信息

BMC Cancer. 2019 May 29;19(1):516. doi: 10.1186/s12885-019-5730-1.

Abstract

BACKGROUND

Adult T-cell leukemia/lymphoma (ATL) is a peripheral T-cell malignancy caused by long-term human T-cell leukemia virus type I (HTLV-1) infection. Survivin-responsive, conditionally replicating adenoviruses regulated by multiple tumor-specific factors (Surv.m-CRAs), in which the expression of the adenoviral early region 1A gene is regulated by the survivin (BIRC5) promoter, can be used to treat several cancers. As survivin is overexpressed in ATL, we examined the effects of Surv.m-CRAs on ATL-selective replication and survival.

METHODS

We tested two ATL cell lines and four HTLV-1-infected T-cell lines. The cells were subjected to infection with either E1-deleted, replication-defective adenoviruses or Surv.m-CRAs at various multiplicities of infection.

RESULTS

Strong activation of survivin promoter was observed in all six cell lines. Moreover, the expression of the coxsackie and adenovirus receptor (CAR), which is important for adenoviral infection, was high in the cell lines. In contrast, we observed the absence of survivin promoter activity and a low expression of CAR in activated peripheral blood lymphocytes (PBLs) from healthy subjects. Surv.m-CRAs actively replicated and induced cytocidal effects in five out of six cell lines; conversely, we observed minimal viral replication and no marked cytotoxicity in normal activated PBLs.

CONCLUSIONS

This is the first report demonstrating that Surv.m-CRAs constitute attractive potential anti-ATL agents.

摘要

背景

成人 T 细胞白血病/淋巴瘤(ATL)是一种由长期人类 T 细胞白血病病毒 I 型(HTLV-1)感染引起的外周 T 细胞恶性肿瘤。受生存素调控、多肿瘤特异性因子调控的条件复制腺病毒(Surv.m-CRAs),其中腺病毒早期区域 1A 基因的表达受生存素(BIRC5)启动子调控,可用于治疗多种癌症。由于生存素在 ATL 中过度表达,我们研究了 Surv.m-CRAs 对 ATL 选择性复制和存活的影响。

方法

我们检测了两种 ATL 细胞系和四种 HTLV-1 感染的 T 细胞系。细胞以不同的感染复数接受 E1 缺失、复制缺陷型腺病毒或 surv.m-CRAs 的感染。

结果

在所有六种细胞系中均观察到生存素启动子的强烈激活。此外,细胞系中细胞表面 Coxsackie 和腺病毒受体(CAR)的表达水平较高,CAR 对腺病毒感染很重要。相反,我们观察到健康供体的激活外周血淋巴细胞(PBLs)中生存素启动子活性缺失和 CAR 表达水平低。Surv.m-CRAs 在五种细胞系中的六种细胞系中均可积极复制并诱导细胞毒性作用;相反,我们观察到在正常激活的 PBLs 中病毒复制很少且无明显细胞毒性。

结论

这是第一个报道表明 Surv.m-CRAs 构成有吸引力的潜在抗 ATL 药物的报告。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8623/6542078/a28697517ca3/12885_2019_5730_Fig1_HTML.jpg

相似文献

2
4
Adenovirus Biology, Recombinant Adenovirus, and Adenovirus Usage in Gene Therapy.
Viruses. 2021 Dec 14;13(12):2502. doi: 10.3390/v13122502.
8
Conditionally replicating adenovirus prevents pluripotent stem cell-derived teratoma by specifically eliminating undifferentiated cells.
Mol Ther Methods Clin Dev. 2015 Aug 12;2:15026. doi: 10.1038/mtm.2015.26. eCollection 2015.

引用本文的文献

1
Tat-dependent conditionally replicating adenoviruses expressing diphtheria toxin A for specifically killing HIV-1-infected cells.
Mol Ther. 2024 Jul 3;32(7):2316-2327. doi: 10.1016/j.ymthe.2024.05.015. Epub 2024 May 11.
2
Correlation analysis of survivin, ING4, CXCL8 and VEGF expression in prostate cancer tissue.
Am J Transl Res. 2021 Dec 15;13(12):13784-13790. eCollection 2021.
3
Adenovirus Biology, Recombinant Adenovirus, and Adenovirus Usage in Gene Therapy.
Viruses. 2021 Dec 14;13(12):2502. doi: 10.3390/v13122502.
4
5
Emerging Importance of Survivin in Stem Cells and Cancer: the Development of New Cancer Therapeutics.
Stem Cell Rev Rep. 2020 Oct;16(5):828-852. doi: 10.1007/s12015-020-09995-4.
6
Oncolytic Adenoviruses: Strategies for Improved Targeting and Specificity.
Cancers (Basel). 2020 Jun 9;12(6):1504. doi: 10.3390/cancers12061504.

本文引用的文献

2
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer.
N Engl J Med. 2016 Nov 10;375(19):1823-1833. doi: 10.1056/NEJMoa1606774. Epub 2016 Oct 8.
3
Multicenter Phase II Study of Lenalidomide in Relapsed or Recurrent Adult T-Cell Leukemia/Lymphoma: ATLL-002.
J Clin Oncol. 2016 Dec;34(34):4086-4093. doi: 10.1200/JCO.2016.67.7732. Epub 2016 Sep 30.
4
Aberrant PD-L1 expression through 3'-UTR disruption in multiple cancers.
Nature. 2016 Jun 16;534(7607):402-6. doi: 10.1038/nature18294. Epub 2016 May 23.
5
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma.
N Engl J Med. 2015 Nov 5;373(19):1803-13. doi: 10.1056/NEJMoa1510665. Epub 2015 Sep 25.
6
Conditionally replicating adenovirus prevents pluripotent stem cell-derived teratoma by specifically eliminating undifferentiated cells.
Mol Ther Methods Clin Dev. 2015 Aug 12;2:15026. doi: 10.1038/mtm.2015.26. eCollection 2015.
7
Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma.
J Clin Oncol. 2015 Sep 1;33(25):2780-8. doi: 10.1200/JCO.2014.58.3377. Epub 2015 May 26.
8
Molecular and genetic properties of tumors associated with local immune cytolytic activity.
Cell. 2015 Jan 15;160(1-2):48-61. doi: 10.1016/j.cell.2014.12.033.
9
Nivolumab in previously untreated melanoma without BRAF mutation.
N Engl J Med. 2015 Jan 22;372(4):320-30. doi: 10.1056/NEJMoa1412082. Epub 2014 Nov 16.
10
Human T-cell leukaemia virus type I and adult T-cell leukaemia-lymphoma.
Lancet Oncol. 2014 Oct;15(11):e517-26. doi: 10.1016/S1470-2045(14)70202-5.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验